Research & Development
Inflammation occurs as a response to tissue injury and serves to protect the human body by eliminating the cause of damage as well as by initiating tissue repair. A dysregulated tissue repair response, as seen during fibrosis development, leads to the accumulation of collagen rich connective tissue (scar tissue), which replaces the original tissue.
Since the scar tissue does not have the specialized structures or functions of the original tissue, functional impairment and organ failure are possible consequences of fibrosis development. Fibrosis contributes to approximately 45% of deaths in the industrial world (Wynn, T.A. et al. 2008) as it represents the final common pathway of virtually all chronic inflammatory diseases. Despite the high prevalence of fibrosis and its enormous impact on human health, there are currently no approved effective agents that can prevent, arrest, or reverse fibrosis.
Fibrogenesis is a complex process involving numerous signaling pathways and cellular interactions. Understanding and defining these different factors will further aid the discovery of new therapeutic target strategies. In vivo models for fibrosis development are crucial tools when testing anti-fibrotic treatments as well as for understanding the fibrogenesis process.
InfiCure Bio has established a unique preclinical model, which spontaneously develops fibrosis in multiple organs e.g. liver and kidneys. The fibrosis development occurs early and has a 100% penetrance, thus making this model a robust and reproducible system to test and validate the effects of novel anti-fibrotic drugs. Although liver fibrosis is the primary focus of InfiCure Bio, we are also investigating fibrosis developments in several other tissues.